Abstract
The pharmaceutical industry still produces the vast majority of their products, from powdered ingredients, in the form of solid doses.
Despite their ubiquity, powders are difficult materials to characterise and understand, as evidenced by the frequent problems encountered during manufacture. The reason for this is their complex rheological behaviour coupled with numerous environmental variations, such as humidity. Equally, the range of processes used to manipulate powders subject them to extremes of stress from high compaction loads seen in compactors to the dispersed state seen in fluidised bed dryers.
Thus, it is evident that ensuring that the powders characteristics are compatible with the way they are to be processed is a clear prerequisite for today’s Quality by Design driven manufacturing.
Modern, computer controlled instrumental techniques, including the dynamic, bulk and shear property measurements have enabled direct measurements of a powders response to aeration, consolidation and flow rate - all at low stresses - as well as quantifying shear and bulk properties (such as density, compressibility and permeability).
In order to demonstrate how fully characterising a powder can be used in the design, operation and troubleshooting of processes, this paper will present examples of common pharmaceutical unit operations and the different powder characteristics that most influence the performance of each.
Keywords: Batch granulation, wet granulation, continuous granulation, mixing, dry powder inhalation, dynamic powder testing, quality by design.
Current Pharmaceutical Design
Title:The Application of Modern Powder Characterisation Methods in Product and Process Development of Solid Dosage Forms
Volume: 21 Issue: 40
Author(s): Tim Freeman, Katrina Brockbank and Brian Armstrong
Affiliation:
Keywords: Batch granulation, wet granulation, continuous granulation, mixing, dry powder inhalation, dynamic powder testing, quality by design.
Abstract: The pharmaceutical industry still produces the vast majority of their products, from powdered ingredients, in the form of solid doses.
Despite their ubiquity, powders are difficult materials to characterise and understand, as evidenced by the frequent problems encountered during manufacture. The reason for this is their complex rheological behaviour coupled with numerous environmental variations, such as humidity. Equally, the range of processes used to manipulate powders subject them to extremes of stress from high compaction loads seen in compactors to the dispersed state seen in fluidised bed dryers.
Thus, it is evident that ensuring that the powders characteristics are compatible with the way they are to be processed is a clear prerequisite for today’s Quality by Design driven manufacturing.
Modern, computer controlled instrumental techniques, including the dynamic, bulk and shear property measurements have enabled direct measurements of a powders response to aeration, consolidation and flow rate - all at low stresses - as well as quantifying shear and bulk properties (such as density, compressibility and permeability).
In order to demonstrate how fully characterising a powder can be used in the design, operation and troubleshooting of processes, this paper will present examples of common pharmaceutical unit operations and the different powder characteristics that most influence the performance of each.
Export Options
About this article
Cite this article as:
Freeman Tim, Brockbank Katrina and Armstrong Brian, The Application of Modern Powder Characterisation Methods in Product and Process Development of Solid Dosage Forms, Current Pharmaceutical Design 2015; 21 (40) . https://dx.doi.org/10.2174/1381612821666151008124159
DOI https://dx.doi.org/10.2174/1381612821666151008124159 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Effects of Heat Shock Protein70
CNS & Neurological Disorders - Drug Targets A Review on a Medicinal and Edible Plant: Aralia elata (Miq.) Seem.
Mini-Reviews in Medicinal Chemistry New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Patent Selections
Recent Patents on Cardiovascular Drug Discovery Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Molecular Interplay between Platelets and the Vascular Wall in Thrombosis and Hemostasis
Current Vascular Pharmacology Efficacy and Toxicity of Clioquinol Treatment and A-beta42 Inoculation in the APP/PSI Mouse Model of Alzheimer's Disease
Current Alzheimer Research The Anti-Inflammatory Effects of Anacardic Acid on a TNF-α - Induced Human Saphenous Vein Endothelial Cell Culture Model
Current Pharmaceutical Biotechnology Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Drug Targets Nutrigenetics of the Postprandial Lipoprotein Metabolism: Evidences From Human Intervention Studies
Current Vascular Pharmacology MicroRNAs in Cardiovascular Therapeutics
Current Topics in Medicinal Chemistry Therapeutic Approaches to Polyglutamine Diseases: Combating Protein Misfolding and Aggregation
Current Pharmaceutical Design Pulmonary Hypertension associated with Congenital Heart Disease
Current Respiratory Medicine Reviews Treatment of Chronic Hepatitis B: From Research to Clinical Practice Via the Consensus Conferences
Current Pharmaceutical Design Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Effect of Antihypertensive Drugs on Cognition and Behavioral Symptoms of Patients with Alzheimer’s Disease: A Meta-analysis
Current Pharmaceutical Biotechnology Cyclooxygenase-2 Biology
Current Pharmaceutical Design Dry Eyes in Rheumatic Disease
Current Rheumatology Reviews